PropertyValue
?:abstract
  • The novel coronavirus outbreak of SARS-CoV-2 first began in Wuhan, China, in December 2019. The most striking manifestation of SARS-CoV-2 is atypical pneumonia and respiratory complications; however, various neurological manifestations are now well recognized. Currently, there have been very few case reports regarding COVID-19 in patients with a known history of myasthenia gravis. Myasthenia gravis (MG) causes muscle weakness, especially respiratory muscles, in high-risk COVID-19 patients, which can lead to severe respiratory compromise. There are few reported cases of severe myasthenia crisis following COVID-19, likely due to the involvement of the respiratory apparatus and the use of immunosuppressive medication. We report the first case of ocular MG developing secondary to COVID-19 infection in a 65-year-old woman. Two weeks prior to hospitalization, the patient suffered from cough, fever, and diarrhea and was found to be positive for COVID-19 via a nasopharyngeal RT-PCR swab test. The electrodiagnostic test showed decremental response over more than 10% on repetitive nerve stimulation test of orbicularis oculi. She tested positive for antibodies against acetylcholine receptor. COVID-19 is known to cause the release of inflammatory cytokines, leading to immune-mediated damage. MG is an immune-mediated disorder caused by molecular mimicry and autoantibodies against the neuromuscular junction.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1007/s00415-020-10263-1
?:journal
  • J_Neurol
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/21d3897f04af7d7e6fa3743ae3e38e1de257cd9a.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7549728.xml.json
?:pmcid
?:pmid
?:pmid
  • 33047223.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review
?:type
?:year
  • 2020-10-12

Metadata

Anon_0  
expand all